AIM: To study changes in the seroprevalence of varicella zoster virus (VZV) antibody over the past 25 years with a view to determining the target age group for any future vaccination strategy. METHODS: Stored sera collected from different age groups over a period of 25 years were tested by a commercial VZV IgG enzyme immunoassay at a four year time interval. Data were analysed by logistic regression to investigate the evidence for changes in incidence and hence seroprevalence over that period. RESULTS: There was a significant rise in VZV antibody prevalence in the 1-4 year age group during the study period. CONCLUSIONS: A universal childhood VZV vaccination strategy will need to take account of the increase in incidence of VZV infection in children under the age of 4 years; hence, the suggested target age would be between 12 and 18 months---soon after the disappearance of maternal antibody.
AIM: To study changes in the seroprevalence of varicella zoster virus (VZV) antibody over the past 25 years with a view to determining the target age group for any future vaccination strategy. METHODS: Stored sera collected from different age groups over a period of 25 years were tested by a commercial VZV IgG enzyme immunoassay at a four year time interval. Data were analysed by logistic regression to investigate the evidence for changes in incidence and hence seroprevalence over that period. RESULTS: There was a significant rise in VZV antibody prevalence in the 1-4 year age group during the study period. CONCLUSIONS: A universal childhood VZV vaccination strategy will need to take account of the increase in incidence of VZV infection in children under the age of 4 years; hence, the suggested target age would be between 12 and 18 months---soon after the disappearance of maternal antibody.
Authors: W S A Smellie; J Forth; J J Coleman; W Irvine; P C Dore; G Handley; D G Williams; P J Galloway; K G Kerr; R Herriot; G P Spickett; T M Reynolds Journal: J Clin Pathol Date: 2006-07-05 Impact factor: 3.411
Authors: George C Wang; Christina Han; Barbara Detrick; Vincenzo Casolaro; David M Levine; Linda P Fried; Jeremy D Walston Journal: J Am Geriatr Soc Date: 2016-04-30 Impact factor: 5.562
Authors: A Mahamud; J Leung; Y Masunu-Faleafaga; E Teshale; R Williams; T Dulski; M Thieme; P Garcia; D S Schmid; S R Bialek Journal: Epidemiol Infect Date: 2013-07-26 Impact factor: 2.451
Authors: Nitu Sengupta; Robert Booy; H J Schmitt; Heikki Peltola; Pierre Van-Damme; R Fabian Schumacher; Magda Campins; Carlos Rodrigo; Terho Heikkinen; Jane Seward; Aisha Jumaan; Adam Finn; Per Olcén; Nancy Thiry; Catherine Weil-Olivier; Judith Breuer Journal: Eur J Pediatr Date: 2007-03-03 Impact factor: 3.860
Authors: P A C Maple; J Haedicke; M Quinlivan; S P Steinberg; A A Gershon; K E Brown; J Breuer Journal: Epidemiol Infect Date: 2016-03-28 Impact factor: 2.451
Authors: Paolo Bonanni; Judith Breuer; Anne Gershon; Michael Gershon; Waleria Hryniewicz; Vana Papaevangelou; Bernard Rentier; Hans Rümke; Catherine Sadzot-Delvaux; Jacques Senterre; Catherine Weil-Olivier; Peter Wutzler Journal: BMC Med Date: 2009-05-28 Impact factor: 8.775